IceCure Medical Ltd. (ICM) - Form 6-K Summary (Nov 2025)

Material Business Update: The company furnished a Form 6-K reporting a significant clinical outcome via press release on November 3, 2025.

• Key Metric: IceCure’s Cryoablation System, when combined with radiation therapy for NSCLC, demonstrated a 92% Disease-Specific 5-year Survival rate.

This data release is incorporated by reference into existing F-3 and S-8 filings.

The reported survival rate represents a critical efficacy benchmark for the company’s core medical device technology in oncology applications.

__CEO